Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” β-catenin and/or glutamine synthetase staining patterns
Am J Clin Pathol · 2025
DOI: 10.1093/ajcp/aqaf115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Am J Clin Pathol, 2025. Verfasst von Hailey L Gosnell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Division, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, United States. Hauptthemen laut MEDLINE: beta Catenin, Glutamate-Ammonia Ligase, Adenoma, Liver Cell, Liver Neoplasms. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective β-Catenin–mutated hepatocellular adenomas (HCAs) carry an increased malignant transformation risk and are screened by interpreting glutamine synthetase (GS) and β-catenin by immunohistochemistry (IHC). Our study aims to assess GS and β-catenin interpretation guidelines for applicability and reproducibility in predicting high-risk HCA and other relevant molecular alterations.
Methods
Hematoxylin and eosin (H&E), β-catenin, GS, and CD34 stains from 75 HCAs were interpreted by three pathologists using Method A (GS interpretation: negative, perivenular patchy, map-like, diffuse, and indeterminate) and Method B criteria (similar GS interpretation scheme based on a recent publication, with and without CD34 expression patterns). Ease of application and interpretation confidence level were assessed. High-risk IHC was defined as nuclear β-catenin and/or diffuse homogeneous GS. Molecular testing was performed on a subset of HCAs and controls.
Results
There were 57 resections and 18 biopsy specimens examined.
Methods
A and B (GS only) were rated as easy to apply, with high interpretation confidence (≥90% using both methods). Consensus rate was comparable in biopsy specimens (100% for both methods) and resections (88% for Method A, 93% for Method B). While the same cases were stratified into high-risk GS categories using both systems, clinically significant genetic alterations (TERT promoter, EGFR, MTOR, and TP53) were identified in 25% of cases stratified as not high risk by IHC.
Conclusions
Both methods have a similar ease of application and level of interpretation confidence, and they also detected β-catenin mutations as expected. Other relevant molecular alterations associated with risk of neoplastic progression and/or bleeding were detected in 25% of HCAs with the non-high-risk IHC phenotype, suggesting the value of molecular testing in this subset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology Division, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, United States.
- Winship Cancer Institute, Emory University, Atlanta, GA, United States.
- Henri Mondor Université Hospital, Créteil, France.
- Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, MN, United States.
- University of California San Francisco Pathology Department, San Francisco, CA, United States.
ORCID-Profile: Hailey L Gosnell, Germán Corredor, Yu-Wei Cheng
Zitieren
APA
Gosnell, H. L., Roberts, D. E., Zhang, X., Azzato, E. M., Jacubowski, M. A., Toro, P., Corredor, G., Cheng, Y. W., Dermawan, J., Calderaro, J., Graham, R. P., Kakar, S., & Allende, D. S. (2025). Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” β-catenin and/or glutamine synthetase staining patterns. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf115
Vancouver
Gosnell HL, Roberts DE, Zhang X, Azzato EM, Jacubowski MA, Toro P, et al. Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” β-catenin and/or glutamine synthetase staining patterns. Am J Clin Pathol. 2025. doi:10.1093/ajcp/aqaf115
BibTeX
@article{Gosnell2025,
author = {Gosnell, Hailey L and Roberts, Daniel E and Zhang, Xuefeng and Azzato, Elizabeth M and Jacubowski, Maureen A and Toro, Paula and Corredor, Germán and Cheng, Yu-Wei and Dermawan, Josephine and Calderaro, Julien and Graham, Rondell P and Kakar, Sanjay and Allende, Daniela S},
title = {Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” β-catenin and/or glutamine synthetase staining patterns},
journal = {Am J Clin Pathol},
year = {2025},
doi = {10.1093/ajcp/aqaf115}
}
EUVIMED